Cargando…

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts

BACKGROUND: Poly-ADP ribose polymerase (PARP) inhibitor-based cancer therapy selectively targets cells with deficient homologous recombination repair. Considering their long-term use in maintenance treatment, any potential mutagenic effect of PARP inhibitor treatment could accelerate the development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Póti, Ádám, Berta, Kinga, Xiao, Yonghong, Pipek, Orsolya, Klus, Gregory T., Ried, Thomas, Csabai, István, Wilcoxen, Keith, Mikule, Keith, Szallasi, Zoltan, Szüts, Dávid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265254/ https://www.ncbi.nlm.nih.gov/pubmed/30425352 http://dx.doi.org/10.1038/s41416-018-0312-6

Ejemplares similares

The Genome of the Chicken DT40 Bursal Lymphoma Cell Line
por: Molnár, János, et al.
Publicado: (2014)

A comprehensive survey of the mutagenic impact of common cancer cytotoxics
por: Szikriszt, Bernadett, et al.
Publicado: (2016)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut
por: Pipek, O., et al.
Publicado: (2017)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions
por: Zámborszky, J, et al.
Publicado: (2017)

Erratum: Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions
por: Zámborszky, J, et al.
Publicado: (2017)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
por: Sambade, Maria J, et al.
Publicado: (2019)

Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort
por: Pipek, Orsolya, et al.
Publicado: (2023)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
por: Diossy, Miklos, et al.
Publicado: (2021)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Niraparib for ovarian cancer
Publicado: (2021)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
por: Genther Williams, Sybil M, et al.
Publicado: (2015)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

FcRn Overexpression Expands Diversity of the Humoral Immune Response in bFcRn Transgenic Mice
por: Szikora, Bence, et al.
Publicado: (2020)

Identification of mutations in SARS-CoV-2 PCR primer regions
por: Mentes, Anikó, et al.
Publicado: (2022)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Evaluation and modulation of DNA lesion bypass in an SV40 large T antigen‐based in vitro replication system
por: Szeltner, Zoltán, et al.
Publicado: (2021)

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
por: van Andel, Lotte, et al.
Publicado: (2017)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

A robust prognostic gene expression signature for early stage lung adenocarcinoma
por: Krzystanek, Marcin, et al.
Publicado: (2016)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

Claudin expression in pulmonary adenoid cystic carcinoma and mucoepidermoid carcinoma
por: Gyulai, Marton, et al.
Publicado: (2023)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

BRCA1 deficiency specific base substitution mutagenesis is dependent on translesion synthesis and regulated by 53BP1
por: Chen, Dan, et al.
Publicado: (2022)

Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
por: Incze, Evelyn, et al.
Publicado: (2023)

Patterns of Somatic Variants in Colorectal Adenoma and Carcinoma Tissue and Matched Plasma Samples from the Hungarian Oncogenome Program
por: Kalmár, Alexandra, et al.
Publicado: (2023)

Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series
por: Gabrail, Nash, et al.
Publicado: (2020)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Characterisation of the spectrum and genetic dependence of collateral mutations induced by translesion DNA synthesis
por: Póti, Ádám, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agk29ag9965vgdvpg174f0so9p